Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease

NCT ID: NCT05521672

Last Updated: 2025-03-20

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-24
• Study Completion Date: 2024-12-13

Brief Summary

A phase II, national, multicenter, uncontrolled and open trial to evaluate the feasibility and safety of laparoscopic administration of adipose derived allogenic mesenchymals stem cells (adMSC), for the treatment of patients with a single inflammatory stenosis in the context of Crohn's disease.

Detailed Description

The hypothesis of the study is that the drug study administration will result in a anti-inflammatory effect, preventing the progression of the stenotic lesion and thus reducing the need to perform surgical resections.

A multicentre, national, uncontrolled and open-label pilot study will be performed. 20 adult patients fulfilling eligibility criteria will be included.

The trial is organized in screening period, treatment period and 6 follow-up visits.

The treatment visit will be done in operating theatre, as the study drug is administrated by laparoscopy with a total dose of 120 million cells prepared in a saline solution with a cell concentration of 10 million cells per millilitre.

Follow-up visits are divided into 4 visits that will take place every 6 weeks (+-7 days) until week 24; 1 additional follow-up visit will take place at week 36 and the last one at week 52.

Analytical controls (blood count, biochemistry and coagulation) will be carried out throughout the trial and biological samples will be taken in three visits (Screening, visit 3 and visit 6).

Abdominal MRI will be performed at baseline and in the end of study visit, to assess stenosis evolution.

The overall duration of the trial is 36 months from the start of recruitment to the last follow-up visit. The period planned for this trial is from september 2022 to september 2025.

Conditions

Stenosis; Bowel; Crohn Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single Dose

This is an uncontrolled trial, phase IIa, proof of concept. Group control has not been included.

All patients will receive one single dose of 120 million cells

Group Type: EXPERIMENTAL

Adipose derived allogenic mesenchymal stem cells (adAMSC)

Intervention Type: DRUG

adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure

Interventions

Adipose derived allogenic mesenchymal stem cells (adAMSC)

adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients who agree to participate and agree to give their written consent.

2. Patients older than 18 years and younger than 75 years

3. With Crohn's disease diagnosed at least 6 months before that meet clinical, endoscopic, histological and/or radiological criteria.

4. Presence of a single inflammatory stenotic lesion in the small intestine or ileocolic area with a maximum length of 5 cm, demonstrated by magnetic resonance enterography, which produces episodes of intestinal occlusion/subocclusion. Other inflammatory lesions are admittedly present, but only one should be identified as the obvious cause of the occlusion/subocclusion.

5. Patients treated with at least one biological drug and with inadequate response to maintenance doses and before intensification (either dose, interval or change/addition of another drug):

1. antiTNF (for at least 14 week, include induction and/or maintenance doses): Infliximab, Adalimumab, Certolizumab.

2. Anti-integrin (for at least 14 week, include induction and/or maintenance doses): Vedolizumab

3. Anti-IL-12/23 (for at least 16 week, include induction and/or maintenance doses): Ustekinumab

6. Women of childbearing potential must have a negative pregnancy test at screening and agree to use effective contraceptive measures for the duration of their participation in the study*

• a woman is considered to be of childbearing potential (WOCBP), that is, fertile, after menarche and until she becomes postmenopausal, unless she is permanently infertile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.

Highly effective methods are considered: combined hormonal contraception (containing estrogens and progestogens) associated with ovulation inhibition (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with ovulation inhibition (oral, injectable, implantable ), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, sexual abstinence

Exclusion Criteria

1. Intra-abdominal abscesses larger than 3 cm not drained (surgically, by interventional radiology) or not treated with antibiotics. Patients may be included once the abscess has been drained (without the need to wait) or if they have received antibiotic treatment, once improvement has been confirmed with imaging tests.

2. Several intestinal obstruction that requires urgent surgery

3. Active outbreak of Crohn's disease requiring medical treatment, defined as abdominal pain, fever, bloody diarrhea and CRP greater than 10. The patient may be included once the condition has resolved, when the patient is on maintenance medication.

4. History of previous invasive neoplasia in the last 5 years. Patients with completely resected basal cell carcinoma of the skin may be included

5. History in the last 6 month of several, progressive or uncontrolled hepatic, hematological, gastrointestinal, renal, endocrine, pulmonary, cardiac, neurological or psychiatric disease

6. Patients with primary sclerosing cholangitis

7. Patients with known congenital or acquired immunodeficiency, including HIV

8. Known allergy or hypersensibility to penicillin or aminoglycosides; DMEN (dulbecco modified eagle´s medium), bovine serum, local anesthesic or gadolinium

9. Contraindication to perform MRI (pacemaker, hip replacement or severe claustrophobia).

10. Patients unwilling or unable to comply with study procedures.

11. Patients who are receiving or have received any investigational drug in the 3 months prior to the screening period

12. Major surgery or severe trauma in the previous 6 months.

13. Pregnant or lactating women.

14. Patients who have a contraindication for general anesthesia.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Effice Servicios Para la Investigacion S.L.

INDUSTRY

Sponsor Role: collaborator

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dolores Herreros

Role: PRINCIPAL_INVESTIGATOR

Hospital Fundación Jiménez Diaz

Locations

Hospital Universitario Valle de Hebrón

Barcelona, , Spain

Hospital Universitario Fundación Jiménez Diaz

Madrid, , Spain

Hospital Universitario y Politécnico La Fe

Valencia, , Spain

Countries

Spain

Other Identifiers

2021-006068-26

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

FJD-MEIC-21-01

Identifier Type: -

Identifier Source: org_study_id